missing translation for 'onlineSavingsMsg'
Få mere at vide
Få mere at vide
STEMCELL Technologies LY2228820 (Dimesylate)
Beskrivelse
- LY2228820 is a trisubstituted imidazole derivative and a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) in vitro (IC50 = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities (Campbell et al.) This product is supplied as the dimesylate salt of the molecule
- Combined with other small molecule inhibitors such as Rapamycin (Catalog #73362) and SR1 (Catalog #72342; Li et al.) or SB203580 (Catalog #72222), Vx702, and BIRB-796 (Catalog #72682), enhances the self-renewal of cord blood-derived hematopoietic stem cells (Baudet et al.)
- By inhibiting p38 MAPK, which is highly expressed in human cancers, LY2228820 is potent and selective at inhibiting tumor growth in animal models of a variety of human cancers (Campbell et al.)
Tekniske data
Tekniske data
| CAS | 862507-23-1 |
| Synonym | Ralimetinib Mesylate; LSN2322600 |
| Mængde | 5 mg |
| Molekylær formel | C24H29FN6 · 2CH3SO3H |
| Renhed | ≥98% |
Produkttitel
Ved at klikke på Send, anerkender du, at du kan blive kontaktet af Fisher Scientific med hensyn til den feedback, du har givet i denne formular. Vi deler ikke dine oplysninger til andre formål. Alle angivne kontaktoplysninger skal også vedligeholdes i overensstemmelse med vores Privatlivspolitik.
Ser du en mulighed for forbedring?